Antibody-directed liposomes: comparison of various ligands for association, endocytosis, and drug delivery.
We have developed and compared the cytotoxicity of methotrexate-gamma-aspartate encapsulated in several liposome formulations which bind mouse monoclonal antibody in order to define conditions for screening cell lines and antibodies for liposomal efficacy. Liposomes conjugated to Staphylococcus aureus Protein A were more potent than liposomes conjugated to either rabbit or affinity-purified goat anti-mouse immunoglobulin (Ig) when incubated with AKR/J SL2 cells sensitized with specific antibody. The antibody-directed Protein A liposomes were also 10-fold more potent than liposomes conjugated directly to specific antibody against the AKR/J SL2. We examined the effect of antibody specificity, concentration, and isotype on liposome-mediated drug delivery to AKR/J SL2 cells. The growth-inhibitory effect of the drug in the antibody-directed Protein A liposomes varied with the target antigen on the cell. The potency of the liposomes with a given antibody was proportional to their relative binding and endocytosis by the cells, and to the reactivity of the particular antibody with the cell as demonstrated by indirect immunofluorescence. The Protein A liposomes maintained maximal potency down to antibody concentrations as low as 1 microgram/ml with the anti-Thy 1.1-sensitized AKR/J SL2 cells, thus demonstrating the possible use of these liposomes for hybridoma screening. Use of isotype-switched variants of the anti-Thy 1.1 antibody with the AKR/J SL2 cells showed the superior efficacy of the IgG2a, IgG2b, and IgG3 isotypes to the IgG1 with the Protein A liposomes. The large differential potency of the free drug and the drug encapsulated in antibody-directed Protein A liposomes was maintained even at short incubation times, thus providing a system which may be useful for eradication of tumor cells from bone marrow in vitro.
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004705:Endocytosis; D007132:Immunoglobulin Isotypes / Q000008:administration & dosage; D008024:Ligands; D008081:Liposomes / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage / Q000031:analogs & derivatives; D013205:Staphylococcal Protein A / Q000008:administration & dosage* / Q000494:pharmacology; D013395:Sucrose / Q000378:metabolism
D000911:Antibodies, Monoclonal; D007132:Immunoglobulin Isotypes; D008024:Ligands; D008081:Liposomes; D013205:Staphylococcal Protein A; D015060:1,2-Dipalmitoylphosphatidylcholine; D013395:Sucrose; C037394:methotrexate-gamma-aspartate; D008727:Methotrexate